000130572 001__ 130572
000130572 005__ 20240126184244.0
000130572 0247_ $$2doi$$a10.1111/aos.13865
000130572 0248_ $$2sideral$$a108172
000130572 037__ $$aART-2018-108172
000130572 041__ $$aeng
000130572 100__ $$aEsteban, O.
000130572 245__ $$aEffect of mitochondrial haplogroups on ranibizumab response in neovascular age-related macular degeneration patients: a pilot study
000130572 260__ $$c2018
000130572 5203_ $$aEditor,
Vascular endothelial growth factor (VEGF) is necessary for the formation of new blood vessels in neovascular age-related macular degeneration (nAMD). Thus, VEGF is a target for antiangiogenic intravitreal therapy in nAMD. One of these anti-VEGF agents is ranibizumab. Besides clinical factors, certain gene variants, that have been associated with nAMD prevalence, also influence the individual’s response to ranibizumab therapy (Dedania et al. 2015). Thus, a significant association between AMD risk and mitochondrial DNA (mtDNA) genetic background (haplogroup) has been repeatedly reported (Udar et al. 2009). We hypothesized that mtDNA genotype could partially explain the individual differences in response to ranibizumab. Patients included in the study were diagnosed of nAMD and received 3 initial monthly injections of intravitreal ranibizumab (IVR) 0.5 mg in 0.05 ml followed by a flexible pro re nata period for the remaining 8 months. The decision to re-treat was based on vision loss =5 letters...
000130572 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000130572 590__ $$a3.153$$b2018
000130572 591__ $$aOPHTHALMOLOGY$$b12 / 59 = 0.203$$c2018$$dQ1$$eT1
000130572 592__ $$a1.51$$b2018
000130572 593__ $$aOphthalmology$$c2018$$dQ1
000130572 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000130572 655_4 $$ainfo:eu-repo/semantics/other$$vinfo:eu-repo/semantics/publishedVersion
000130572 700__ $$0(orcid)0000-0001-9876-5850$$aAscaso, F.J.$$uUniversidad de Zaragoza
000130572 700__ $$aMateo, J.
000130572 700__ $$aCalvo, T.
000130572 700__ $$0(orcid)0000-0003-1770-6299$$aMontoya, J.$$uUniversidad de Zaragoza
000130572 700__ $$0(orcid)0000-0002-0269-7337$$aRuiz-Pesini, E.$$uUniversidad de Zaragoza
000130572 7102_ $$11004$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Oftalmología
000130572 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000130572 773__ $$g97, 1 (2018), e133 - e134$$pActa ophthamol.$$tACTA OPHTHALMOLOGICA$$x1755-375X
000130572 8564_ $$s157423$$uhttps://zaguan.unizar.es/record/130572/files/texto_completo.pdf$$yVersión publicada
000130572 8564_ $$s3463241$$uhttps://zaguan.unizar.es/record/130572/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130572 909CO $$ooai:zaguan.unizar.es:130572$$particulos$$pdriver
000130572 951__ $$a2024-01-26-18:10:49
000130572 980__ $$aARTICLE